Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/00
A61K-031/445
A61K-031/4535
A61K-009/20
출원번호
US-0275485
(2008-11-21)
등록번호
US-8945592
(2015-02-03)
발명자
/ 주소
Pushpala, Shamim
Hamel, Larry
Tzannis, Stelios
Cruz, Evangeline
출원인 / 주소
AcelRx Pharmaceuticals, Inc.
대리인 / 주소
Cooley LLP
인용정보
피인용 횟수 :
4인용 특허 :
142
초록
Compositions and methods effective to minimize or eliminate the presence of oxidative degradation products in solid dosage forms comprising sufentanil are provided.
대표청구항▼
1. A packaged solid sufentanil drug dosage form comprising: (a) a solid sufentanil drug dosage form;(b) a primary package containing said solid sufentanil drug dosage form and an oxygen scavenger, wherein the percentage of sufentanil oxidative degradation products is minimized or eliminated in a sol
1. A packaged solid sufentanil drug dosage form comprising: (a) a solid sufentanil drug dosage form;(b) a primary package containing said solid sufentanil drug dosage form and an oxygen scavenger, wherein the percentage of sufentanil oxidative degradation products is minimized or eliminated in a solid sufentanil drug dosage form packaged with said oxygen scavenger relative to a solid sufentanil drug dosage form packaged in the absence of an oxygen scavenger. 2. The packaged solid sufentanil drug dosage form according to claim 1, wherein the drug dosage form has a mass of less than 30 mg or a volume of less than 30 mcL. 3. The packaged solid sufentanil drug dosage form according to claim 1, wherein the drug dosage form has a mass of less than 10 mg or a volume of less than 10 mcL. 4. The packaged solid sufentanil drug dosage form according to claim 1, wherein the amount of sufentanil in said solid sufentanil drug dosage form is selected from the group consisting of 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, 40 mcg, 50 mcg, 60 mcg, 70 mcg, 80 mcg and 100 mcg of sufentanil. 5. The packaged solid sufentanil drug dosage form according to claim 2, wherein the amount of sufentanil in said solid sufentanil drug dosage form is selected from the group consisting of 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, 40 mcg, 50 mcg, 60 mcg, 70 mcg, 80 mcg and 100 mcg of sufentanil. 6. The packaged solid sufentanil drug dosage form according to claim 3, wherein the amount of sufentanil in said solid sufentanil drug dosage form is selected from the group consisting of 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, 40 mcg, 50 mcg, 60 mcg, 70 mcg, 80 mcg and 100 mcg of sufentanil. 7. The packaged solid sufentanil drug dosage form according to claim 1, wherein said solid sufentanil drug dosage form is stored for at least 6 months under conditions selected from the group consisting of 5° C. and ambient humidity, 25° C. and 60% relative humidity and 40° C. and 75% relative humidity. 8. The packaged solid sufentanil drug dosage form according to claim 5, wherein said solid sufentanil drug dosage form is stored for at least 6 months under conditions selected from the group consisting of 5° C. and ambient humidity, 25° C. and 60% relative humidity and 40° C. and 75% relative humidity. 9. The packaged solid sufentanil drug dosage form according to claim 6, wherein said solid sufentanil drug dosage form is stored for at least 6 months under conditions selected from the group consisting of 5° C. and ambient humidity, 25° C. and 60% relative humidity and 40° C. and 75% relative humidity. 10. The packaged solid sufentanil drug dosage form according to claim 1, further comprising a drug delivery dispenser for housing said solid sufentanil drug dosage form. 11. The packaged solid sufentanil drug dosage form according to claim 10, wherein the drug delivery dispenser is a cartridge. 12. The packaged sufentanil solid sufentanil drug dosage form according to claim 11, wherein the cartridge comprises a desiccant. 13. The packaged solid sufentanil drug dosage form according to claim 10, wherein the drug delivery dispenser is a single dose applicator. 14. The packaged solid sufentanil drug dosage form according to claim 10, wherein the primary package is a foil pouch. 15. The packaged solid sufentanil drug dosage form according to claim 11, wherein the primary package is a foil pouch. 16. The packaged solid sufentanil drug dosage form according to claim 13, wherein the primary package is a foil pouch. 17. The packaged solid sufentanil drug dosage form according to claim 14, wherein oxidative degradation of the sufentanil in said solid sufentanil drug dosage form is not detectable after 6 months of storage at 5° C. and ambient humidity, 25° C. and 60% relative humidity or 40° C. and 75% relative humidity. 18. A method for minimizing or eliminating oxidative degradation of a solid sufentanil drug dosage form comprising: (a) providing a solid sufentanil drug dosage form in a drug delivery dispenser;(b) further providing an oxygen scavenger;(c) placing said drug delivery dispenser and said oxygen scavenger in a primary package made of a substantially oxygen impermeable material, wherein the percentage of sufentanil oxidative degradation products is minimized or eliminated in said solid sufentanil drug dosage form packaged with said oxygen scavenger relative to a solid sufentanil drug dosage form packaged in the absence of an oxygen scavenger. 19. The method according to claim 18, wherein the drug dosage form has a mass of less than 30 mg or a volume of less than 30 mcL. 20. The method according to claim 18, wherein the drug dosage form has a mass of less than 10 mg or a volume of less than 10 mcL. 21. The method according to claim 18, wherein the amount of sufentanil in said solid sufentanil drug dosage form is selected from the group consisting of 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, 40 mcg, 50 mcg, 60 mcg, 70 mcg, 80 mcg and 100 mcg of sufentanil. 22. The method according to claim 18, wherein the solid sufentanil drug dosage form is stored for at least 6 months under conditions selected from the group consisting of 5° C. and ambient humidity, 25° C. and 60% relative humidity and 40° C. and 75% relative humidity. 23. The method according to claim 18, wherein said drug delivery dispenser is a cartridge. 24. The method according to claim 23, wherein the cartridge comprises a desiccant. 25. The method according to claim 18, wherein the drug delivery dispenser is a single dose applicator. 26. The method according to claim 18, wherein the primary package is a foil pouch.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (142)
Lee Eun S. (Redwood City CA) Goetz Victor (Philadelphia PA), Abusable substance dosage form having reduced abuse potential.
Jones J. Bryan,CAX ; Plettner Erika, Chemically modified mutant enzymes and methods for producing them, and screening them for amidase and/or esterase activity.
Rajadhyaksha Vithal J. (27436 Esqina Mission Viejo CA 92691), Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers for physiological active a.
Stanley Theodore H. (Salt Lake City UT) Hague Brian (West Valley City UT), Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments.
Hodges, Craig C.; Lloyd, Peter M.; Mufson, Daniel; Rogers, Daniel D.; Wensley, Martin J., Delivery of aerosols containing small particles through an inhalation route.
Pather, S. Indiran; Robinson, Joseph R.; Eichman, Jonathan D.; Khankari, Rajendra K.; Hontz, John; Gupte, Sangeeta V., Effervescent drug delivery system for oral administration.
Pather, S. Indiran; Robinson, Joseph R.; Eichman, Jonathan D.; Khankari, Rajendra K.; Hontz, John; Gupte, Sangeeta V., Effervescent drug delivery system for oral administration.
Pather, S. Indiran; Robinson, Joseph R.; Eichman, Jonathan D.; Khankari, Rajendra K.; Hontz, John; Gupte, Sangeeta V., Effervescent drug delivery system for oral administration.
S. Indiran Pather ; Joseph R. Robinson ; Jonathan D. Eichman ; Rajendra K. Khankari ; John Hontz ; Sangeeta V. Gupte, Effervescent drug delivery system for oral administration.
S. Indiran Pather ; Joseph R. Robinson ; Jonathan D. Eichman ; Rajendra K. Khankari ; John Hontz ; Sangeeta V. Gupte, Effervescent drug delivery system for oral administration.
Ayache Josiane (Grenoble FRX) Ayache Jean-Jacques (Grenoble FRX) Bruttmann Georges (Grenoble FRX) Pedrali Patrick (Annecy FRX) Robert Serge (Braine le Chateau BEX), Galenical forms of beta-2-mimetics for administration perlingually and sublingually.
Hadaway Michelle A. (Gurnee IL) Kramer David E. (Northbrook IL) Best Robert J. (Winthrop Harbor IL), Holder and packaging for a hardened medicated matrix.
Johnson, Randolph Mellus; Theeuwes, Felix; Gillis, Edward M.; Litmanovitz, Dana; Laidlaw, Barbara; Brown, James; Culwell, John; Filice, James A.; Wickman, Peter; Yum, Su-Il; Poutiatine, Andrew; Dinka, Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners.
Rubsamen Reid M. (Berkeley CA) Lloyd Lester J. (Orinda CA) Johansson Eric T. (Dublin CA), Lockout device for controlled release of drug from patient-activated dispenser.
Rubsamen Reid M. (Berkeley CA) Lloyd Lester J. (Orinda CA) Johansson Eric T. (Dublin CA), Lockout device for controlled release of drug from patient-activateddispenser.
Erickson Victor (c/o George Spector ; 3615 Woolworth Bldg. ; 233 Broadway New York NY 10007) Spector George (3615 Woolworth Bldg. ; 233 Broadway New York NY 10007), Medication dispenser.
Overy, Michael Robert; Sullivan, Michael James, Method and apparatus for enhancing security in a wireless network using distance measurement techniques.
Phipps, Joseph B.; Southam, Mary; Bernstein, Keith J.; Noorduin, Henk, Method and device for transdermal electrotransport delivery of fentanyl and sufentanil.
Nagai Tsuneji (Chofu JPX) Machida Yoshiharu (Kawasaki JPX) Suzuki Yoshiki (Hino JPX) Ikura Hiroshi (Hino JPX), Method and preparation for administration to the mucosa of the oral or nasal cavity.
Fishman Jack (Miami FL) Arnold John (Fairway KS) Sherman Fred (Hollywood FL) Hsiao Jane (Copper City FL), Method of safely providing anesthesia or conscious sedation.
Kehr Bruce A. ; Sohn Evan ; Maurer David ; Baumel Irwin D. ; Stempler David S., Method, apparatus and operating system for managing the administration of medication and medical treatment regimens.
Stanley Theodore H. (Salt Lake City UT) Haque Brian (West Valley City UT), Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics.
Pather, S. Indiran; Robinson, Joseph R.; Eichman, Jonathan D.; Khankari, Rajendra K.; Hontz, John, Pharmaceutical compositions for rectal and vaginal administration.
Smith Maree,AUX ; Ross Fraser,AUX, Production of analgesic synergy by co-administration of sub-analgesic doses of a MU opioid agonist and a kappa-2 opioid agonist.
Romick Jerome M. (Artromick International ; Inc. ; 4800 Hilton Corp. Dr. Columbus OH 43232), Unit-dose medication dispenser and multiple-dispenser frame therefor.
Aljadeff, Daniel; Granot, Yair; Tsruya, Shalom; Amsalem, Reuven, Wireless local area network (WLAN) channel radio-frequency identification (RFID) tag system and method therefor.
Palmer, Pamela; Poutiatine, Andrew I; Rampersaud, Charles; Edwards, Bruce; Chiu, Edmond; Schreck, Thomas; Tzannis, Stelios; Hamel, Larry, Methods for administering small volume oral transmucosal dosage forms using a dispensing device.
Palmer, Pamela; Schreck, Thomas; Tzannis, Stelios; Hamel, Larry; Poutiatine, Andrew I., Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain.
Palmer, Pamela; Schreck, Thomas; Tzannis, Stelios; Hamel, Larry; Poutiatine, Andrew I., Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain.
Palmer, Pamela; Schreck, Thomas; Tzannis, Stelios; Hamel, Larry; Poutiatine, Andrew I., Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.